To include your compound in the COVID-19 Resource Center, submit it here.

CureTech's CT-011 meets lymphoma endpoint

CureTech Ltd. (Yavne, Israel) said CT-011 met the primary endpoint in a Phase

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE